{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:59:51Z","timestamp":1790675991514,"version":"4.1.0"},"reference-count":85,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>SARS-CoV-2 causes severe acute respiratory syndrome, which has led to significant morbidity and mortality around the world. Since its emergence, extensive prophylactic and therapeutic countermeasures have been employed to successfully prevent the spread of COVID-19. Extensive work has been undertaken on using monoclonal antibody therapies, mass vaccination programs, and antiviral drugs to prevent and treat COVID-19. However, since antiviral drugs could take years to become widely available, immunotherapy and vaccines currently appear to be the most feasible option. In December 2020, the first vaccine against SARS-CoV-2 was approved by the World Health Organization (WHO) and, subsequently, many other vaccines were approved for use by different international regulators in different countries. Most monoclonal antibodies (mAbs) and vaccines target the SARS-CoV-2 surface spike (S) protein. Recently, mutant (or variant) SARS-CoV-2 strains with increased infectivity and virulence that evade protective host antibodies present either due to infection, antibody therapy, or vaccine administration have emerged. In this manuscript, we discuss the different monoclonal antibody and vaccine therapies available against COVID-19 and how the efficacy of these therapies is affected by the emergence of variants of SARS-CoV-2. We also discuss strategies that might help society cope with variants that could neutralize the effects of immunotherapy and escape the protective immunity conferred by vaccines.<\/jats:p>","DOI":"10.3390\/vaccines9080914","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T21:17:06Z","timestamp":1629235026000},"page":"914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines"],"prefix":"10.3390","volume":"9","author":[{"given":"Ahmed","family":"Yaqinuddin","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1202-7214","authenticated-orcid":false,"given":"Areez","family":"Shafqat","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5056-8222","authenticated-orcid":false,"given":"Junaid","family":"Kashir","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"},{"name":"Department of Comparative Medicine, King Faisal Specialist Hospital and Research Center, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Alkattan","sequence":"additional","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"637378","DOI":"10.3389\/fmolb.2021.637378","article-title":"A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials","volume":"8","author":"Venkadapathi","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/d41586-021-00958-4","article-title":"The race for antiviral drugs to beat COVID\u2014And the next pandemic","volume":"592","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"Ahn","year":"2020","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_4","first-page":"43","article-title":"Vaccines for COVID-19: The current state of play","volume":"35","author":"Koirala","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.12998\/wjcc.v8.i19.4280","article-title":"Role of monoclonal antibody drugs in the treatment of COVID-19","volume":"8","author":"Ucciferri","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1016\/S2666-5247(20)30144-0","article-title":"Viral presence and immunopathology in patients with lethal COVID-19: A prospective autopsy cohort study","volume":"1","author":"Schurink","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","article-title":"Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy","volume":"183","author":"Du","year":"2020","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1126\/science.abc6952","article-title":"A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41467-021-23036-9","article-title":"A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation","volume":"12","author":"Kang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jones, B.E., Brown-Augsburger, P.L., Corbett, K.S., Westendorf, K., Davies, J., Cujec, T.P., Wiethoff, C.M., Blackbourne, J.L., Heinz, B.A., and Foster, D. (2021, August 16). Title: LY-CoV555, A Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in A Non-human Primate Model of SARS-CoV-2 Infection, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/33024963\/.","DOI":"10.1101\/2020.09.30.318972"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa2029849","article-title":"SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with COVID-19","volume":"384","author":"Chen","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1854149","DOI":"10.1080\/19420862.2020.1854149","article-title":"Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline","volume":"12","author":"Tuccori","year":"2020","journal-title":"MAbs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with COVID-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1038\/s41598-021-83108-0","article-title":"Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes","volume":"11","author":"Batra","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3390\/v6082991","article-title":"The coronavirus nucleocapsid is a multifunctional protein","volume":"6","author":"McBride","year":"2014","journal-title":"Viruses"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Patel","year":"2020","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","article-title":"COVID-19 vaccine development and a potential nanomaterial path forward","volume":"15","author":"Shin","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_29","first-page":"1","article-title":"Multivalent Nanoparticle-Based Vaccines Protect Hamsters Against SARS-CoV-2 After a Single Immunization","volume":"4","author":"Chiba","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing Antiviral B Cell Responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","first-page":"1","article-title":"A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","article-title":"A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","volume":"592","author":"Plante","year":"2021","journal-title":"Nature"},{"key":"ref_34","unstructured":"(2021, August 05). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_35","unstructured":"(2021, August 05). SARS-CoV-2 Variant Classifications and Definitions, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-info.html#Concern."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Khan, A., Zia, T., Suleman, M., Khan, T., Ali, S.S., Abbasi, A.A., Mohammad, A., and Wei, D.Q. (2021, August 16). Higher Infectivity of the SARS-CoV-2 New Variants is Associated with K417N\/T, E484K, and N501Y Mutants: An Insight from Structural Data, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/33755190\/.","DOI":"10.1002\/jcp.30367"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Liu, Y., Liu, J., Plante, K.S., Plante, J.A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., and Schindewolf, C. (2021, August 16). The N501Y spike substitution enhances SARS-CoV-2 transmission. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.03.08.434499v1.","DOI":"10.1101\/2021.03.08.434499"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Das, S., Agarwal, A., Singh, S., and Abraham, P. (2021, August 16). Convergent Evolution of SARS-CoV-2 Spike Mutations, L452R, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.04.22.440932v1.","DOI":"10.1101\/2021.04.22.440932"},{"key":"ref_39","unstructured":"Ferreira, I., Datir, R., Papa, G., Kemp, S., Meng, B., Singh, S., Pandey, R., Ponnusamy, K., Radhakrishnan, V., and Sato, K. (2021, August 16). SARS-CoV-2 B.1.617 Emergence and Sensitivity to Vaccine-Elicited Antibodies. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.05.08.443253v2."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/d41586-021-00121-z","article-title":"Fast-spreading COVID variant can elude immune responses","volume":"589","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","article-title":"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies","volume":"184","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.chom.2021.03.008","article-title":"SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera","volume":"29","author":"Kuzmina","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0140-6736(21)00628-0","article-title":"Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012\/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial","volume":"397","author":"Emary","year":"2021","journal-title":"Lancet"},{"key":"ref_47","unstructured":"(2021, May 18). Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial | Johnson & Johnson. Available online: https:\/\/www.jnj.com\/johnson-and-johnson-announces-single-shot-janssen-Covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","article-title":"Efficacy of NVX-CoV2373 COVID-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Shinde","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Edara, V.-V., Lai, L., Sahoo, M.K., Floyd, K., Sibai, M., Solis, D., Flowers, M.W., Hussaini, L., Ciric, C.R., and Bechnack, S. (2021, August 16). Infection and Vaccine-Induced Neutralizing Antibody Responses to the SARS-CoV-2 B.1.617.1 Variant. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.05.09.443299v1.","DOI":"10.1101\/2021.05.09.443299"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109415","DOI":"10.1016\/j.celrep.2021.109415","article-title":"SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination","volume":"36","author":"Hoffmann","year":"2021","journal-title":"Cell Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijid.2021.07.029","article-title":"Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case","volume":"110","author":"Connor","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/d41586-021-00367-7","article-title":"How \u2018killer\u2019 T cells could boost COVID immunity in face of new variants","volume":"590","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"ref_55","unstructured":"Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., and Team, M.L. (2021, August 16). Vaccine-Induced Immunity Provides More Robust Heterotypic Immunity than Natural Infection to Emerging SARS-CoV-2 Variants of Concern. Available online: https:\/\/www.researchsquare.com\/article\/rs-226857\/v1."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.xcrm.2021.100204","article-title":"Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1473-3099(21)00287-5","article-title":"Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac","volume":"21","author":"Chen","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_58","unstructured":"(2021, August 03). View of COVID-19 Vaccines in Pakistan: Efficacy, Adverse Effects and Availability. Available online: https:\/\/www.jimdc.org.pk\/index.php\/JIMDC\/article\/view\/723\/544."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1039\/C5BM00360A","article-title":"Nanostructures for protein drug delivery","volume":"4","author":"Lopes","year":"2016","journal-title":"Biomater. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1016\/j.vaccine.2009.03.034","article-title":"Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy","volume":"27","author":"Demento","year":"2009","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"109906","DOI":"10.1016\/j.mehy.2020.109906","article-title":"Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1\u03b2\/neutrophil extracellular traps feedback loop","volume":"143","author":"Yaqinuddin","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.resinv.2020.06.001","article-title":"COVID-19: Role of neutrophil extracellular traps in acute lung injury","volume":"58","author":"Yaqinuddin","year":"2020","journal-title":"Respir. Investig."},{"key":"ref_63","first-page":"24","article-title":"The central role of neutrophil extracellular traps in SARS-CoV-2-induced thrombogenesis and vasculitis","volume":"15","author":"Yaqinuddin","year":"2020","journal-title":"African J. Respir. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Reinke, S., Thakur, A., Gartlan, C., Bezbradica, J.S., and Milicic, A. (2020). Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants. Vaccines, 8.","DOI":"10.3390\/vaccines8030554"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Volpatti, L.R., Wallace, R.P., Cao, S., Raczy, M.M., Wang, R., Gray, L.T., Alpar, A.T., Briquez, P.S., Mitrousis, N., and Marchell, T.M. (2021, August 16). Polymersomes Decorated with SARS-CoV-2 Spike Protein Receptor Binding Domain Elicit Robust Humoral and Cellular Immunity. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.04.08.438884v1.","DOI":"10.1021\/acscentsci.1c00596"},{"key":"ref_66","first-page":"1","article-title":"Theory, simulations and the design of functionalized nanoparticles for biomedical applications: A Soft Matter Perspective","volume":"3","year":"2017","journal-title":"npj Comput. Mater."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fimmu.2019.00022","article-title":"Nanoparticle-Based Vaccines Against Respiratory Viruses","volume":"10","author":"Gauthier","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/wnan.45","article-title":"Nanoparticle vaccines against respiratory viruses","volume":"1","author":"Adair","year":"2009","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/postgradmedj-2020-138577","article-title":"COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment","volume":"97","author":"Parasher","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"ref_70","unstructured":"(2021, August 06). 6 July 2021 Episode 150: Mucosal Immunity and Vaccination: Will Intranasal Vaccines Be the \u201cGame Changers\u201d to Prevent Infection? | ICPCovid. Available online: https:\/\/www.icpcovid.com\/en\/news\/6-july-2021-episode-150-mucosal-immunity-and-vaccination-will-intranasal-vaccines-be-game."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1126\/scitranslmed.abf1555","article-title":"Enhanced SARS-CoV-2 neutralization by dimeric IgA","volume":"13","author":"Wang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00250-09","article-title":"Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies","volume":"17","author":"Mapletoft","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3251","article-title":"Recent progress in mucosal vaccine development: Potential and limitations","volume":"12","author":"Lycke","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11259-011-9484-8","article-title":"Mucosal immunization provides better protection than subcutaneous immunization against Pasteurella multocida (B:2) in mice preimmunized with the outer membrane proteins","volume":"35","author":"Kharb","year":"2011","journal-title":"Vet. Res. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"6276","DOI":"10.1016\/j.vaccine.2009.04.074","article-title":"PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants","volume":"27","author":"Ichinohe","year":"2009","journal-title":"Vaccine"},{"key":"ref_76","first-page":"729","article-title":"Advantages of Intranasal Vaccination and Considerations on Device Selection","volume":"71","author":"Birkhoff","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Van Doremalen, N., Purushotham, J.N., Schulz, J.E., Holbrook, M.G., Bushmaker, T., Carmody, A., Port, J.R., Yinda, C.K., Okumura, A., and Saturday, G. (2021, August 16). Intranasal ChAdOx1 nCoV-19\/AZD1222 Vaccination Reduces Shedding of SARS-CoV-2 D614G in Rhesus Macaques. Short Title: Mucosal Vaccine Reduces Shed SARS-CoV-2. Available online: https:\/\/www.biorxiv.org\/content\/10.1101\/2021.01.09.426058v1.","DOI":"10.1101\/2021.01.09.426058"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-021-03594-0","article-title":"Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses","volume":"594","author":"Saunders","year":"2021","journal-title":"Nature"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"ref_81","unstructured":"(2021, August 06). Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted with or without AS03 (COVID-19)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04750343."},{"key":"ref_82","unstructured":"(2021, August 06). Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted with Aluminum Hydroxide (COVID-19)\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04742738."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1080\/21645515.2017.1356952","article-title":"Developments in the formulation and delivery of spray dried vaccines","volume":"13","author":"Kanojia","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s11095-014-1419-y","article-title":"Biomaterials for Nanoparticle Vaccine Delivery Systems","volume":"31","author":"Sahdev","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_85","unstructured":"(2021, August 06). Altimmune Announces Update on AdCOVID\u2122 Phase 1 Clinical. Available online: https:\/\/www.globenewswire.com\/news-release\/2021\/06\/29\/2255167\/0\/en\/Altimmune-Announces-Update-on-AdCOVID-Phase-1-Clinical-Trial.html."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/8\/914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:45:34Z","timestamp":1760165134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/8\/914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":85,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["vaccines9080914"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9080914","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]}}}